We report a superior tRNASec variant (tRNAUTuX) that facilitates EF-Tu dependent stoichiometric Sec insertion in response to UAG both in vivo in Escherichia coli and in vitro in a cellfree protein synthesis system.
The amino acid substitutions resulting in a partial change of specificity were identified and combined into one superior variant designated NN1.
Comparative association tests consistently demonstrated the g.66493737C>T SNP as the superior variant in the prediction of distance aptitude in racehorses (g.66493737C>T, P = 1.02 × 10-10; BIEC2-417495, Punadj. = 1.61 × 10-9).
Linkage disequilibrium produces deviations of variant counts towards the superior variant, not only at the genetic marker site(s) causative to the phenotype of interest, but also in genetic marker sites closely located to these causative marker sites.
Next, plasmids harboring the genes coding for these proteins are transformed in the target strain, after which a screening for the phenotype of interest takes place to select superior variants.
In other cases, it is difficult to directly select superior variants.
In brief, drug resistance cassettes are randomly inserted into the genome by transposition, after which the obtained collection of mutants is screened for superior variants (Hamer et al., 2001).
Perhaps the greatest promise lies in the combination of carefully selecting the best strains from the immense natural biodiversity, followed by a (combination of) technique(s) to further improve these natural yeasts in order to generate superior variants for industrial use.
Using an isometric plank exergame it was found that participants performed significantly better than in a solo control condition in all variants with a superior virtual partner (ie, whether coacting, additive, or conjunctive).
The combination of stable heterologous gene expression, synthesis and secretion of high concentrations of recombinant proteins, the advantageous characteristics of the H. polymorpha expression system, would appear to provide the means for developing a production process for a potentially clinically superior rSAK variant.
In toto, these properties of IgG2σ suggest that it is a superior alternative to previously described IgG variants of minimal effector function, for future therapeutic applications of non-immunostimulatory mAb and Fc-fusion platforms.
